GI
CSTL icon

GAMMA Investing’s Castle Biosciences CSTL Stock Holding History

GAMMA Investing’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453 Sell
19
-27
-59% -$601 ﹤0.01% 3997
2026
Q1 		$1.13K Sell
46
-6
-12% -$197 ﹤0.01% 3808
2025
Q4 		$2.02K Hold
52
– – ﹤0.01% 3595
2025
Q3 		$1.18K Sell
52
-80
-61% -$1.63K ﹤0.01% 3581
2025
Q2 		$2.69K Sell
132
-86
-39% -$1.59K ﹤0.01% 3318
2025
Q1 		$4.36K Sell
218
-4
-2% -$99 ﹤0.01% 3136
2024
Q4 		$5.92K Buy
222
+49
+28% +$1.49K ﹤0.01% 2847
2024
Q3 		$4.93K Buy
173
+36
+26% +$916 ﹤0.01% 2748
2024
Q2 		$2.98K Buy
137
+16
+13% +$357 ﹤0.01% 2751
2024
Q1 		$2.68K Buy
121
+100
+476% +$2.18K ﹤0.01% 2651
2023
Q4 		$485 Buy
+21
New +$370 ﹤0.01% 2972

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAMMA Investing's CSTL Position: Q2 2026 in Review

GAMMA Investing reduced its Castle Biosciences (CSTL) stake by 59% in Q2 2026, selling an estimated $601 and leaving 19 shares worth $453. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

GAMMA Investing first reported a position in CSTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $5.92K in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • GAMMA Investing held 19 shares of Castle Biosciences worth $453 as of Q2 2026.
  • GAMMA Investing sold 27 Castle Biosciences shares in Q2 2026, an estimated $601.
  • Castle Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3997 holding.
  • GAMMA Investing first reported a position in Castle Biosciences in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Castle Biosciences position peaked at $5.92K in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.